US$6.4m revenue and 45.2% margin mark stronger Adheris quarter

Pipeline expansion tests Adheris's strategic reset

Adheris Health Limited (ASX:AHE) has produced a materially stronger quarter against its recent trough, with revenue, gross profit and margins all improving from the June quarter as the company builds toward the next pharmaceutical budgeting cycle. The more consequential measure may be the sales funnel: as at 23 October, Adheris counted close to 110 opportunities across more than 40 clients and almost 90 brands.

That pipeline rose across every disclosed measure since 21 August, including a 14.1% increase in total value and a 25.1% increase in weighted value. More than half its value is now tied to higher-margin THRiV and digital engagement programs, while about half comprises seven-figure opportunities. The company said no individual program or brand represented more than 10% of total pipeline value, limiting concentration within the prospective workload.

The update extends the shift outlined in Adheris's FY26 strategic reset, which focused on cost reduction, US operations and higher-margin digital offerings. In Q1 FY27, GLP-1 programs accounted for 19% of revenue, up from 6% a year earlier, while specialty medicine rose to 22% from 17%. General medicine remained the largest category at 39%.

Revenue and gross margin rebound from June quarter

Revenue reached US$6.4 million, up 1.6% from Q1 FY26 and 60.5% from Q4 FY26. Gross profit climbed 8.4% year on year to US$2.9 million and more than doubled from the prior quarter, while gross margin expanded to 45.2% from 42.4% a year earlier. Adheris attributed the improvement to stronger out-of-cycle bookings, customer win-backs, existing-program add-ons, lower platform costs and improved execution.

Underlying product margin was 52.2%, up 2.5 percentage points year on year. The company also completed its scalable-operations initiative, integrated a top-five pharmacy partner onto a new technology system and signed a contract for its first program featuring its AI Patient Concierge. Those developments are reported as operating milestones; the filing does not quantify revenue from the new digital program or the expected financial contribution from the technology integration.

Cash position leaves little room for execution error

The improvement in trading metrics came alongside a US$3.079 million net operating cash outflow. Cash receipts were US$3.2 million, affected by lower opening receivables, longer collection cycles linked to greater agency-channel activity and the absence of Australian receipts. Staff costs fell to US$2.2 million and administration and corporate costs to US$374,000, but cash declined by US$3.0 million during the quarter to US$3.524 million.

On the Appendix 4C calculation, that balance represents 1.14 quarters of funding based on the quarter's operating outflow. Adheris said the period included higher-than-normal payments that were not expected to recur, does not currently anticipate needing additional funding, and expects to continue operations on the basis of existing cash and expected operating cash flows. That assessment makes the conversion of the CY27 pipeline into signed programs and receipts particularly important, even though the company has not provided a new revenue forecast.

There is also a customer-reach setback. One of Adheris's largest pharmacy partners will stop participating in sponsored programs from 1 January 2027, reducing total addressable patient reach. The company said the departure is not expected to affect its FY27 budgeted revenue, and said the disclosed pipeline already reflects the change, but the effect on future growth and program scale remains to be demonstrated.

Earn-out and litigation add separate sources of uncertainty

The first of three potential earn-out payments linked to the sale of Adheris's Australian and New Zealand business is close to finalisation, with the amount still to be agreed and received. The transaction was part of the ANZ sale earn-out structure, which included future payments beyond the initial consideration. Adheris said it will make a separate ASX announcement once the first earn-out amount is settled.

Meanwhile, wholly owned US subsidiary Adheris LLC is defending proceedings brought by Mindsprint Pte. Ltd. in the US District Court for the Southern District of New York. Mindsprint seeks damages of at least US$2.3 million plus costs and argues that certain agreements were terminated for convenience rather than cause. Adheris disputes the claims, says the case is at an early stage and cannot yet reliably quantify any financial impact.